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Purpose: Multiparametric magnetic resonance imaging (mpMRI) with informed targeted 
biopsies (TGBX) has changed the paradigm of prostate cancer (PCa) diagnosis. 
Randomized studies have demonstrated a diagnostic benefit of Clinically significant 
(CS) for TGBX compared to standard systematic biopsies (SBX). We aimed to evaluate 
whether mpMRI-informed TGBX has superior diagnosis rates of any-, CS-, high-grade 
(HG)-, and clinically insignificant (CI)-PCa compared to SBX in biopsy-naïve men. 
Methods: Data was searched in Medline, Embase, Web of Science, and Evidence-
based medicine reviews-Cochrane Database of systematic reviews from database 
inception until 2019. Studies were selected by two authors independently, with 
disagreements resolved by consensus with a third author.  Overall 1951 unique 
references were identified, and 100 manuscripts underwent full-text review. Data were 
pooled using random-effects models. The meta-analysis is reported according to the 
PRISMA statement. The study protocol is registered with PROSPERO 
(CRD42019128468). 
Results: Overall 29 studies (13,845 patients) were analyzed. Compared to SBX, use of 
mpMRI-informed TGBX was associated with a 15% higher rate of any PCa diagnosis 
(95% CI 10-20%, p<0.00001). This relationship was not affected by the study 
methodology (p=0.11). Diagnosis of CS and HG PCa were more common in the 
mpMRI-informed TGBX group (risk difference of 11%, 95% CI 0-20%, p=0.05, and 2%, 
95% CI 1-4%; p=0.005, respectively) while there was no difference in diagnosis of CI 
PCa (risk difference of 0, 95% CI -3-3%, p=0.96). Notably, the exclusion of SBX in the 
mpMRI-informed TGBX arm significantly modified the association between a mpMRI 
strategy and lower rates of CI PCa diagnosis (p=0.01) without affecting the diagnosis 
rates of CS- or HG-PCa. 
Conclusions: In comparison to SBX, a mpMRI-informed TGBX strategy results in a 
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mpMRI-informed TGBX was associated with decreased rates of CI-PCa diagnosis 
without affecting diagnosis of CS- or HG-PCa. 
1. Introduction  
     Prostate cancer (PCa) diagnosis by systematic random histologic sampling of the 
prostate has, until recently, been the standard of care1. Transrectal ultrasound (TRUS)-
guided 12-core template systematic biopsy (SBX) has been widely recommended for 
men at risk for PCa2_ENREF_2. However, SBX templates are limited by inherent random 
and systematic errors. Specific regions of the prostate are consistently underesampled, 
including the anterior region and apex3, and, unless hypoechoic lesions are seen on 
TRUS, sampling occurs by chance. Thus, SBX can miss up to 20% of CS PCa, 
resulting in underdiagnosis4. Additionally, SBX detects a relatively high percentage of 
clinically insignificant (CI) PCa (Gleason grade group [GGG] 1), which may result in 
overtreatment2, if proper use of active surveillance (AS) is not practiced. 
     With the introduction of multiparametric prostate magnetic resonance imaging 
(mpMRI), the pathways for PCa diagnosis have changed. MpMRI is unique in that it can 
both risk-stratify men for prostate biopsy (PB) and allow anatomic guidance for biopsy. 
The spatial information provided by mpMRI allows for precise mpMRI-informed targeted 
biopsy (TGBX), where clinically significant (CS) PCa (≥GGG 25) is detected with fewer 
biopsy cores6, and diagnosis of CI PCa decreases7. There are randomized studies 
demonstrating the superior diagnosis rate of TGBX in diagnosing CS PCa in biopsy-
naïve men8, 9. However, TGBX has limitations, missing CS PCa in 2.1-15% of cases10-
13. Although the most recent European Association of Urology (EAU)2 and the National 
institute for Health and Care Excellence (NICE)14 guidelines recommend performing 
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widely adopted in North-America, where mpMRI is usually reserved for men with a 
previous negative biopsy. Furthermore, the added benefit of combining SBX with TGBX 
remains unclear with conflicting data supporting both TGBX alone7, 15 and combining 
SBX with TGBX16. The combination appears to detect more CS PCa than TGBX alone4, 
7. Both the EAU and American Association of Urology (AUA) guidelines currently 
recommend adding SBX in men with a suspicious mpMRI lesion undergoing TGBX2, 17.  
     To synthesize the available data on these questions, we undertook a systematic 
review and meta-analysis of all studies comparing SBX and TGBX, either alone or in 
combination with SBX, to assess the detection rate of any PCa, CS PCa, high grade 
(HG) PCa (GGG>=4) and CI PCa in biopsy-naïve men. 
 
2. Methods  
     This systematic review and meta-analysis is reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement18. The 
study protocol was registered with PROSPERO CRD42019128468. 
2.1. Research question 
     Is mpMRI-informed TGBX with or without SBX associated with higher rates of any-, 
CI-, CS-, and HG-PCa diagnosis than SBX alone in biopsy-naïve men at risk of PCa?  
2.2. Types of Studies 
     Randomized clinical trials and observational cohort studies were included. Other 
publications including editorials, commentaries, review articles, meeting abstracts and 
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dissertations or theses) were excluded. Only studies with paired cohorts, with patients 
with a positive mpMRI receiving either TGBX alone or together with SBX were included. 
To prevent duplication of patients used in our analyses, we selected one study (when 
more than one was published on the same patient cohort), based on contemporary 
timing, cohort size, and granularity of data reported. Our main interest was to compare 
the outcomes of mpMRI-informed TGBX alone or in combination with SBX to SBX 
outcomes in biopsy-naïve men. Thus, studies comparing mpMRI-guided TGBX and 
SBX in biopsy-naïve men were included and those in men with prior negative biopsy or 
with prior PCa diagnosis were excluded. 
2.3. Outcome measures 
The primary outcome of interest was the rate of any PCa diagnosis. Secondary 
outcomes were rates of CS PCa (GGG ≥ 2), HG PCa (GGG ≥ 4) and CI PCa (GGG=1). 
2.4. Search strategy  
     Medline, EMBASE, Web of Science, Scopus and EBM Reviews Cochrane Database 
of Systematic Reviews databases were searched using the OvidSP platform for studies 
indexed from database inception to February 15, 2019 by a professional medical 
librarian. We used both subject headings and text-word terms for “prostate cancer”, 
“prostate neoplasm”, “biopsy”,” no prior”, “no previous”, “naïve”, “ultrasound”, “magnetic 
resonance imaging”, “systematic”, “targeted”, and related and exploded terms including 
MeSH terms in combination with keyword searching. A full search strategy is presented 
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2.5. Study review methodology 
     The study selection was conducted by two authors (A.E.A. and T.C.) independently. 
Disagreements were resolved by consensus with a third author (H.G.). Titles and 
abstracts were used to screen for initial study inclusion. Full-text review was used where 
abstracts were insufficient to determine if the study met inclusion criteria. A data 
extraction form was created and piloted prior data extraction, which was performed by a 
single author (A.E.A.) and subsequently verified by two additional authors (H.G. and 
Z.K.) independently. 
2.6. Risk of bias assessment 
     The Cochrane Collaboration’s tool for assessing risk of bias19 and the Newcastle-
Ottawa Scale (NOS) were used for risk of bias assessment in randomized clinical trials 
and cohort studies, respectively. The NOS assesses risk of bias in three domains20: (1) 
selection of the study groups; (2) comparability of groups; and (3) ascertainment of 
exposure and outcome21. Studies with scores >=7 were considered as having a low risk 
of bias, scores of 4–6 as having a moderate risk of bias, and scores <4 as having a high 
risk of bias. 
2.7. Assessment of heterogeneity  
     Heterogeneity was assessed using the Q test, and estimated using the 
DerSimonian-Laird method, and finally quantified using I2 values22. Given the identified 
clinical heterogeneity, we employed random effects models for each of our analyses. 
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     We expressed the outcome as the risk difference for PCa diagnosis between 
mpMRI-informed TGBX and SBX. This was determined as the proportion of patients 
diagnosed with PCa in the SBX group minus the proportion of patients diagnosed in the 
mpMRI-informed TGBX group. Therefore, a risk difference less than zero (negative risk 
difference) indicates that PCa diagnosis was more frequent in the mpMRI-informed 
TGBX group while a risk difference greater than zero (positive risk difference) indicates 
that PCa diagnosis was more frequent in the SBX group. 
 We used the Mantel-Haenszel method for meta-analysis of dichotomous data 
using the risk difference as our measure of effect. For each outcome, we first performed 
meta-analysis among three strata defined by study methodology (randomized controlled 
trials, prospective cohort studies, and retrospective cohort studies) as differences in 
study methodology may reasonably be expected to affect study conclusions. We tested 
for subgroup differences between strata for each outcome using the Chi-squared test. 
Where the Chi-squared test for subgroup differences was insignificant, we pooled 
results for each outcome across the study methodologies to provide a single pooled 
effect estimate. Where the Chi-squared test for subgroup differences was significant 
(p<0.05), we deemed it inappropriate to pool results and thus reported pooled results 
among each stratum individually. 
 We performed a priori subgroup analysis to assess whether inclusion of SBX in 
the mpMRI-informed TGBX arm would affect the risk difference for PCa diagnosis 
between mpMRI-informed TGBX and SBX for each outcome. Again, we tested for 
subgroup differences between strata for each outcome using the Chi-squared test to 
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Meta-analysis was performed using Review Manager 5.3 (Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2014) software. Statistical significance 
was determined at p<0.05. 
 
3. Results  
3.1. Literature search results 
     We identified 1951 unique references (Figure 1). 100 manuscripts underwent full-text 
review and 29 studies were selected for final analyses. Reasons for exclusion are 
provided in Figure 1. 19 studies (65.5%) enrolled patients prospectively, however only 5 
studies (17.2%) randomly assigned patients to mpMRI-informed TGBX or SBX group. 
Publication details of all included studies can be found in Appendix 2. 
3.2. Characteristics of identified studies 
     Studies were conducted in 4 continents (65.5% in Europe, 20.7% in Asia, 6.9% in 
the US, and 6.9% in Australia), and 89.7% were conducted after 2010 (Table 1). 21 
studies (72.5%) were from single centers, three studies (10.3%) analyzed two centers 
and five studies (17.2%) were multicenter.  
Across the 29 included studies, there were 13,845 patients, of whom 1,085 
(7.8%) patients were enrolled in randomized trials. Nearly all studies included men 
based on an elevated prostate specific antigen (PSA) and/or an abnormal digital rectal 
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With respect to MRI performance and interpretation, 21 studies (72.4%) used 3 
Tesla mpMRI and 8 (27.6%) used 1.5 Tesla. The Prostate Imaging Reporting and Data 
System (PIRADS) was employed in most studies (21 [72.4%]), while 7 studies (24.1%) 
used the Likert and similar 4- or 5-point scales. 14 studies (48.3%) included SBX in 
addition to mpMRI-informed TGBX in the mpMRI arm. Targeted biopsy was performed 
with an ultrasound fusion biopsy technique in 18 studies (62.1%). Cognitive fusion 
biopsy and in-bore fusion biopsy were used in 8 (27.6%) and 2 studies (7%), 
respectively. Most studies (24, 82.7%) utilized transrectal biopsy. 
     All studies reported on overall PCa and CS PCa detection rate, defined based on 
Gleason score and/or maximum PCa core length (Table 1). However, for our analysis, 
we considered CS PCa to be GGG>=2 alone5. 
3.3. Risk of bias assessment 
All randomized controlled trials included concealed random sequence generation 
and were similarly at low risk of attrition and reporting bias (Supplementary Table 1). 
While all studies were unblinded and thus potentially at risk for performance and 
detection bias, it is improbable that this should influence the outcome of PCa diagnosis. 
     The risk of bias in the prospective and retrospective cohort studies was low in all 
included studies (supplementary table 2). In some studies, patients with negative 
mpMRI were excluded which may have potentially introduced selection bias. As the 
outcome of interest was overall PCa or CS PCa diagnosis rate, all studies were deemed 
to have adequate follow up. 
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3.4.1. Any prostate cancer diagnosis 
 Assessing the association between use of mpMRI-informed TGBX or SBX and 
rates of any PCa diagnosis, we pooled results from 29 studies representing 31 unique 
patient cohorts and 13,845 participants. Among randomized controlled trials (5 studies, 
1,085 participants), the use of mpMRI-informed TGBX +/- SBX was associated with a 
16% increased likelihood of PCa diagnosis (risk difference = -0.16, 95% CI -0.22 to -
0.11; p<0.00001; I2 = 4%) when compared to SBX alone (Figure 2a). Among 14 
prospective cohort studies (5,508 participants), the use of mpMRI-informed TGBX +/- 
SBX was associated with a 20% increased likelihood of PCa diagnosis (risk difference = 
-0.20, 95% CI -0.27 to -0.12; p<0.00001; I2 = 89%) compared to SBX alone (Figure 2a). 
Finally, among 10 retrospective cohort studies (7,252 participants), the use of mpMRI-
informed TGBX +/- SBX was associated with a 9% increased likelihood of PCa 
diagnosis (risk difference = -0.09, 95% CI -0.16 to -0.01; p=0.03; I2 = 89%) compared to 
SBX alone (Figure 2a). The test for subgroup differences was insignificant (chi-squared 
= 4.40, p=0.11; I2 = 54.5%). Thus, we pooled results across these strata: assessing all 
13,845 participants from 29 studies, the use of mpMRI-informed TGBX +/- SBX was 
associated with a 15% increased likelihood of PCa diagnosis (risk difference = -0.15, 
95% CI -0.20 to -0.10; p<0.00001; I2 = 89%) compared to SBX alone (Figure 2a). 
 We then assessed whether inclusion of SBX in the mpMRI-informed TGBX arm 
affected the observed association between mpMRI-informed TGBX and any PCa 
diagnosis. Among cohorts where data was available for patients in the mpMRI-informed 
TGBX arm who had targeted biopsy alone (22 studies, 75.9%), the use of mpMRI-
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difference = -0.12, 95% CI -0.18 to -0.07; p<0.00001; I2 = 89%) compared to SBX alone 
(Figure 3a). For cohorts where data was available for patients who received both TGBX 
and SBX (14 studies, 48.3%), the use of mpMRI-informed TGBX was associated with a 
17% increased likelihood of PCa diagnosis (risk difference = -0.17, 95% CI -0.24 to -
0.09; p<0.00001; I2 = 91%) compared to SBX alone (Figure 3a). The test for subgroup 
differences was insignificant (chi-squared = 0.78, p=0.38; I2 = 0%) suggesting that the 
inclusion of SBX in patients undergoing mpMRI-informed TGBX does not modify the 
association between mpMRI-informed TGBX and rates of any PCa diagnosis.  
3.4.2. Clinically significant prostate cancer diagn osis 
 Twenty-seven studies (13,089 participants) provided data for meta-analysis of 
the outcome of CS PCa. There was an increased likelihood of CS PCa diagnosis 
among randomized controlled trials (risk difference = -0.11, 95% CI -0.2 to 0.00; p=0.05; 
I2 = 78%), among prospective cohort studies (risk difference = -0.18, 95% CI -0.24 to -
0.11; p<0.00001; I2 = 81%) and among retrospective cohort studies (risk difference = -
0.07, 95% CI -0.12 to -0.02; p=0.004; I2 = 77%) (Figure 2b). However, the test for 
subgroup differences was significant (chi-squared = 6.35, p=0.04; I2 = 68.5%). Thus, we 
did not pool results across strata of study methodology. We found no evidence of effect 
modification due to inclusion of SBX in the mpMRI-informed TGBX arm on the 
relationship between mpMRI-informed TGBX, and rates of CS PCa diagnosis (test for 
subgroup differences chi-squared = 0.18, p=0.67; I2 = 0%) (Figure 3b). 
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 Similarly, 27 studies (13,089 participants) provided data for meta-analysis of the 
outcome of CI PCa. The use of mpMRI-informed TGBX +/- SBX was associated with no 
meaningful difference in the likelihood of CI PCa diagnosis, whether assessed among 
randomized controlled trials (risk difference = 0.01, 95% CI -0.09 to 0.11; p=0.85; I2 = 
82%), prospective cohort studies (risk difference = 0.00, 95% CI -0.05 to 0.05; p=0.99; 
I2 = 79%) or retrospective cohort studies (risk difference = -0.01, 95% CI -0.05 to 0.04; 
p=0.83; I2 = 84%) (Figure 2c). The test for subgroup differences was insignificant (chi-
squared = 0.08, p=0.96; I2 = 0%). Thus, we pooled results across strata of study 
methodology and found no meaningful difference in the likelihood of CI PCa diagnosis 
(risk difference = 0.00, 95% CI -0.03 to 0.03; p=0.96; I2 = 80%) (Figure 2c).  
Interestingly, there was evidence of effect modification due to the inclusion of 
SBX in the mpMRI-informed TGBX arm for this outcome (test for subgroup differences 
chi-squared = 6.49, p=0.01; I2 = 84.6%): while studies which included SBX in the 
mpMRI-informed TGBX arm demonstrated a 4% higher rate of diagnosis of CI PCa 
among patients who received mpMRI-informed TGBX+SBX, compared to SBX alone 
(risk difference = -0.04, 95% CI -0.08 to -0.00; p=0.05; I2 = 77%), those which utilized 
TGBX alone demonstrated a 3% lower rate of diagnosis of CI PCa among patients who 
received mpMRI-informed TGBX, compared to SBX alone (risk difference = 0.03, 95% 
CI -0.01 to 0.06; p=0.11; I2 = 75%) (Figure 3c). 
3.4.4. High-grade prostate cancer diagnosis 
A smaller subset of 19 studies (9,811 participants) provided data for meta-
analysis of the outcome of HG PCa. The use of mpMRI-informed TGBX +/- SBX was 
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randomized controlled trials, albeit with a small effect size (risk difference = -0.04, 95% 
CI -0.07 to -0.01; p=0.004; I2 = 0%) compared to SBX alone (Figure 2d). Among 
prospective cohort studies (risk difference = -0.02, 95% CI -0.05 to 0.01; p=0.23; I2 = 
66%) and retrospective cohort studies (risk difference = -0.02, 95% CI -0.06 to 0.01; 
p=0.12; I2 = 38%) (Figure 2d), this effect was not significant though the direction and 
magnitude were similar. The test for subgroup differences was insignificant (chi-squared 
= 1.72, p=0.42; I2 = 0%). Thus, we pooled results across strata of study methodology 
and found the use of mpMRI-informed TGBX was associated with a small but 
significantly higher likelihood of HG PCa diagnosis (risk difference = -0.02, 95% CI -0.04 
to -0.01; p=0.005; I2 = 47%) compared to SBX alone (Figure 2d). We found no evidence 
of effect modification due to inclusion of SBX in the mpMRI-informed TGBX arm on the 
relationship between mpMRI-informed TGBX and rates of HG PCa diagnosis (test for 
subgroup differences chi-squared = 0.40, p=0.53; I2 = 0%) (Figure 3d). 
 
4. Discussion  
    In this meta-analysis of biopsy-naïve patients undergoing a PB, we compared rates of 
PCa diagnosis for patients undergoing standard SBX and mpMRI-informed TGBX. Our 
analyses demonstrate several findings. First, patients who underwent a mpMRI-
informed TGBX +/- SBX were 15% more likely to be diagnosed with any PCa than 
patients who underwent standard SBX. Further, this improved diagnostic yield was not 
affected by whether a mpMRI-informed biopsy was performed with TGBX alone or 
combined with SBX. Second, patients who underwent mpMRI-informed biopsy were 
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diagnosis rate of CI PCa compared to those who underwent SBX alone. Third, 
exclusion of SBX in the mpMRI-informed TGBX arm was associated with decreased 
rates of CI PCa diagnosis (p=0.01) without meaningfully affecting diagnosis rates of 
any-, CS-, or HG PCa. 
     Standard TRUS-guided SBX remains the most common technique used worldwide in 
biopsy-naïve patients deemed to warrant PB. While affected by characteristics of the 
population under study, PCa detection rates are approximately 40-45% for SBX23. 
Despite this, TRUS-SBX harbors low sensitivity and specificity in the diagnosis of 
PCa12: repeat biopsy identifies PCa in 10-25% of men with an initially negative biopsy24. 
Further, TRUS-SBX underestimates tumor grade in 36% of men when compared to 
radical prostatectomy (RP)25. With the advent of mpMRI, the sensitivity of PCa imaging 
has improved26. Previous meta-analyses have shown that mpMRI-informed TGBX 
detects more CS PCA, with fewer cores than utilized in TRUS-guided SBX13.  
     More than 70% of studies included in this analysis used 3 tesla mpMRI and 
incorporated the PIRADS system for interpretation of imaging. However similar results 
were seen in studies using 1.5 tesla mpMRI, and other reporting systems such as the 
Likert scale. Included studies utilized numerous strategies for TGBX including 
ultrasound-, cognitive-, and in-bore-fusion biopsies, all of which have demonstrated an 
increased detection rate of CS PCa when compared to SBX27-29. Presently, there is no 
consensus on which strategy is superior.  
    We identified a higher rate of CS PCa diagnosed with mpMRI-informed biopsy 
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RCTs. This is on par with results of prior meta-analyses11-13, 30. Uniquely, this analysis 
found mpMRI-informed biopsy identified higher rates of HG PCa.  
     More actionably, we found that exclusion of SBX in the mpMRI-informed TGBX arm 
significantly modified the association between mpMRI and CI PCa diagnosis (p=0.01), 
without meaningfully affecting diagnostic rates of CS- or HG PCa. Thus, in contrast to 
the common hypothesis that the combination of TGBX+SBX yields a higher diagnosis 
rate of any and CS PCa31, these data suggest that SBX may be safely omitted in men 
undergoing mpMRI-guided biopsy. This approach would be expected to decrease the 
over-detection of clinically indolent PCa. Further, using TGBX only, a lower number of 
biopsy cores are required to reach a diagnosis, leading to less discomfort and 
morbidity32, 33. Lastly, emerging data suggest that decreased number of biopsy-cores 
can lead to less blood loss during RP34.  
This analysis strengthens the body of evidence supporting mpMRI as a risk-
stratification tool in biopsy-naïve men, showing that a positive mpMRI can lead to a 
higher detection rate of CS PCa. Our manuscript adds to the current knowledge and 
supports other recently published meta-analyses demonstrating that TGBX has a clear 
benefit over SBX alone in the diagnosis of CS PCa30, 35-37. Over a million men in the US 
undergo TRUS-guided SBX each year38, at a cost of nearly 1 billion dollars, with less 
than 10% of the 12 million biopsy core samples demonstrating cancer. According to the 
PROMIS study39, approximately 25% of the biopsies (250,000) could be avoided in 
patients with a negative pre-biopsy mpMRI. But, for patients with a positive mpMRI, our 
study shows that they could go down from a 12-core biopsy to only a 4-core biopsy 
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cores processed per year. This supports the concept of an mpMRI-first strategy in 
biopsy-naïve men as an effective and cost-effective approach for the diagnosis of CS 
PCa40. However, we must not forget that if an mpMRI-first strategy in biopsy-naïve men 
is adopted, the cost of mpMRI must be taken into consideration when analyzing the 
cost-effectiveness of this entire approach. Taken together, the added benefit of SBX is 
shown to be questionable in the setting of biopsy-naïve men suspected to have PCa, 
and its role must be reconsidered, possibly omitted, as recommended in men with a 
previous negative biopsy2. 
     No difference was noted in the diagnosis rate of CI PCa between mpMRI-informed 
biopsy and SBX. In contrast, three prior meta-analyses have demonstrated a lower rate 
of CI PCa diagnosis with TGBX when compared to SBX11, 12, 30 while Valerio et al. 
showed that most studies demonstrated a higher rate of CI PCa in the mpMRI-informed 
biopsy pathology13. As discussed above, this may be affected using SBX in the TGBX 
group. In our meta-analysis, TGBX alone or combined with SBX demonstrate an equal 
rate of CS PCa diagnosis rate but TGBX alone resulted in a 4% reduction in CI PCa 
diagnosis. The definition of CI PCa varies between studies, ranging from the Epstein 
criteria41 to the combination of maximal cancer core length <6 mm with GGG 142. In our 
analysis, we used the simplified definition of GGG=1 alone, which could explain some of 
the discrepancies between our analysis and others. 
          The strength of our analysis includes a comprehensive search strategy and 
actionable data due to the use of mpMRI protocols in accordance with the current 
recommended imaging guidelines. However, there are several limitations. First, mpMRI-
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across the studies with regards to the interpretation of suspicious MRI lesions, the 
decision on when to biopsy, method of TGBX, the number of cores taken, and the 
different stages of the learning curve of the radiologists who interpreted the imaging. 
Second, there was significant heterogeneity among many of the comparisons included 
in this review. We used random effects models to pool these studies as a result. Third, 
this analysis focused on biopsy-naïve men and these results may not be applicable to 
those with a previous negative biopsy. Fourth, this analysis only applies to patients with 
a positive mpMRI. For patients with a negative mpMRI, the current role of SBX remains 
controversial. Notably, previous analyses have demonstrated a CS PCa diagnosis rate 
of 12% on systematic biopsy of men with negative mpMRI43, making the role of SBX far 
from obsolete, especially with a negative mpMRI. SBX is still crucial in many settings 
and understanding when it is mandatory and when not is imperative. Furthermore, when 
considering management with focal therapy, SBX might have a critical role of ruling out 
additional disease outside the target lesion. Importantly, aside from the changing 
radiologist learning curve of interpreting mpMRI images, the ease of properly obtaining 
an mpMRI-targeted biopsy around the world varies due to a plethora of considerations, 
and thus the conclusion of this study may not be applicable worldwide.  Lastly, there is a 
potential methodological error in assuming that one type of biopsy diagnoses more CS-
PCa than another based on the results of PB alone. Deciphering which strategy is better 
from a diagnostic perspective, would be to analyze the RP specimens of all patients 
who underwent either a TGBX or SBX and compare the rate of CS PCa in the final 
specimen to the preoperative biopsy result. Indeed, a recently published study showed 
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tertiary high-score location. This resulted in reporting a higher biopsy GGG and 
subsequent downgrading of the final pathologic specimen following RP44. 
 
5. Conclusions  
     Based on a comprehensive, current meta-analysis, a mpMRI-informed TGBX 
strategy in men undergoing their first PB resulted in a significantly higher diagnosis rate 
of any-, CS-, and HG-PCa, compared to SBX. Furthermore, exclusion of SBX for men 
undergoing mpMRI-informed TGBX was associated with decreased rates of CI PCa 
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Figure 1. – Preferred Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA) flow chart 
 
Figure 2. Forest plot for meta-analysis of the difference in prostate cancer diagnosis 
between patients assessed using systematic biopsy or mpMRI-informed biopsy, 
stratified by study methodology: (a) any prostate cancer diagnosis, (b) clinically-
significant prostate cancer diagnosis, (c) clinically-insignificant prostate cancer 
diagnosis, (d) high-grade prostate cancer diagnosis. 
 
Figure 3. Forest plot for meta-analysis of the difference in prostate cancer diagnosis 
between patients assessed using systematic biopsy or mpMRI-informed biopsy, 
stratified by inclusion of systematic biopsy in the mpMRI-informed biopsy arm: (a) any 
prostate cancer diagnosis, (b) clinically-significant prostate cancer diagnosis, (c) 
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Table 1-Characteristics of included studies 
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CS=clinically significant; GGG=Gleason grade group; PSA=Prostate specific antigen, NR=Not reported; MRI=magnetic resonance imaging; 
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Figure 2. Forest plot for meta-analysis of the difference in prostate cancer diagnosis between patients 
assessed using systematic biopsy or mpMRI-informed biopsy, stratified by study methodology: (a) any 
prostate cancer diagnosis, (b) clinically-significant prostate cancer diagnosis, (c) clinically-insignificant 
prostate cancer diagnosis, (d) high-grade prostate cancer diagnosis. 
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Figure 3. Forest plot for meta-analysis of the difference in prostate cancer diagnosis between patients 
assessed using systematic biopsy or mpMRI-informed biopsy, stratified by inclusion of systematic 
biopsy in the mpMRI-informed biopsy arm: (a) any prostate cancer diagnosis, (b) clinically-significant 
prostate cancer diagnosis, (c) clinically-insignificant prostate cancer diagnosis, (d) high-grade prostate 
cancer diagnosis. 
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